Trial reportClinical lymphoma, myeloma & leukemia2013
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.
Trial report in Clinical lymphoma, myeloma & leukemia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 65 citations in OpenAlex.
- Homoharringtonine: mechanisms, clinical applications and research progress.Frontiers in oncology · 2025Review
- Tamoxifen induces radioresistance through NRF2-mediated metabolic reprogramming in breast cancer.Cancer & metabolism · 2023Article
- How I Manage Patients with Chronic Myeloid Leukemia (CML): Perspectives from Clinical Practice.Blood and lymphatic cancer : targets and therapy · 2022Article
- Wogonin reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12-CXCR4/7 axis in bone marrow microenvironment.Annals of translational medicine · 2020Article
- Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway.Frontiers in oncology · 2019Article
- Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia.Therapeutic advances in hematology · 2019Review
- A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected.Oncology and therapy · 2018Review
- Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.Molecular cancer · 2018Review
- Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate.Leukemia & lymphoma · 2016Article
- Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses.Blood cancer journal · 2015Article
- An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians.Korean journal of family medicine · 2015Review
- Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.Clinical lymphoma, myeloma & leukemia · 2015Review
- Article
- Homoharringtonine, a clinically approved anti-leukemia drug, sensitizes tumor cells for TRAIL-induced necroptosis.Cell communication and signaling : CCS · 2015Article
- Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Targeting translation initiation in breast cancer.Translation (Austin, Tex.) · 2014Review
- Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.OncoTargets and therapy · 2014Review
- [Evolution of chronic myeloid leukemia on nilotinib after failure of imatinib].The Pan African medical journal · 2014Observational
- Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors.Haematologica · 2013Article
- Cephalotaxus Alkaloids.The Alkaloids. Chemistry and biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 7 countries.
Funding
Abstract
introductionOmacetaxine mepesuccinate (omacetaxine) is a first-in-class cephalotaxine that has demonstrated efficacy in CML. In this analysis we evaluated omacetaxine in CML patients with resistance or intolerance to 2 or more tyrosine kinase inhibitors (TKIs). PATIENTS AND
methodsData were pooled from 2 phase II trials of subcutaneous omacetaxine, administered at 1.25 mg/m(2) twice daily for 14 consecutive days every 28 days until response, then for 7 days every 28 days as maintenance. Patients with resistance or intolerance to imatinib and at least 1 other approved TKI (dasatinib and/or nilotinib) were included; results for patients in chronic phase (CP) are reported here. Major cytogenetic response (MCyR) was the primary end point.
resultsEighty-one patients with CML-CP (median age, 59 years; range, 26-83 years) were included in the analysis. All patients previously received imatinib, 69 (85%) previously received dasatinib, and 48 (59%) previously received nilotinib. Median omacetaxine exposure was 7.5 months (range, 0.03-38.6 months), with 13 patients ongoing. MCyR was reported in 16 patients (20%; one-sided 95% lower confidence limit, 12.8%), including 8 complete responses; median duration was 17.7 months (95% confidence interval, 4.1 months - not reached). Fifty-six patients (69%) achieved and/or maintained hematologic response for at least 8 weeks; median duration was 12.2 months (range, 8.4-26.2 months). Median failure-free and overall survival were 9.6 months and 34 months, respectively. Toxicity was mainly hematologic: the most common grade 3/4 adverse events were thrombocytopenia (67%), neutropenia (47%), and anemia (37%).
conclusionOmacetaxine produced clinically meaningful responses with acceptable tolerability in patients with CML-CP previously treated with 2 or more TKIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.